[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100454358":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":25,"locations":31,"responsibleParty":62,"collaborators":24,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":66,"sex":72,"minAge":73,"maxAge":24,"enrollmentInfo":74,"targetDuration":24,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":84,"overallStatus":34,"whyStopped":24,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"University Hospital, Strasbourg, France","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental group","ACTIVE_COMPARATOR","Surgery for disc herniation and intraoperative periradicular administration of PRF",[13],"Biological: Treatment",{"label":15,"type":10,"description":16,"interventionNames":17},"Control group","Surgery for disc herniation alone (i.e. reference treatment).",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"BIOLOGICAL","Treatment","Experimental product: product derived from autologous blood, obtained after centrifugation.\n\nTreatment modalities: intraoperative periradicular administration of autologous PRF.",[15,9],null,[26],{"name":27,"role":28,"phone":29,"phoneExt":24,"email":30},"Erci SALVAT","CONTACT","+33 3 88 12 85 02","eric.salvat@chru-strasbourg.fr",[32],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Les Hôpitaux Universitaires","RECRUITING","Strasbourg","Bas-Rhin","67091","France","FR",{"type":41,"coordinates":42},"Point",[43,44],7.74553,48.58392,{"lat":44,"lon":43},[47,49,52,54,56,58,60],{"name":48,"role":28,"phone":29,"phoneExt":24,"email":30},"Eric SALVAT",{"name":50,"role":51,"phone":24,"phoneExt":24,"email":24},"Daniel TIMBOLSCHI IONUT","SUB_INVESTIGATOR",{"name":53,"role":51,"phone":24,"phoneExt":24,"email":24},"Lauriane JOGANAH",{"name":55,"role":51,"phone":24,"phoneExt":24,"email":24},"André MULLER",{"name":57,"role":51,"phone":24,"phoneExt":24,"email":24},"Yohann BOHREN",{"name":59,"role":51,"phone":24,"phoneExt":24,"email":24},"François PROUST",{"name":61,"role":51,"phone":24,"phoneExt":24,"email":24},"Hugo Andres COCA",{"type":63,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100454358","phase-3-efficacy-of-an-intraoperative-periradicular-application-of-platelet-rich-fibrin-prf-on-the-intensity-of-residual-post-surgical-neuropathic-pain-after-a-surgery-for-disc-herniation-100454358",false,"NCT05196503","Efficacy of an Intraoperative Periradicular Application of Platelet Rich Fibrin (PRF) on the Intensity of Residual Post-surgical Neuropathic Pain After a Surgery for Disc Herniation","Efficacy of Platelet Rich Fibrin in the Prevention of Residual Neuropathic Pain Following Disc Herniation Surgery","NeuroPRF","Inclusion criteria:\n\n* Patient, male or female, \\>18 years old at the time of signing informed consent;\n* Patient for whom a diagnosis of radiculopathy on lumbar disc herniation has been made, and for whom surgery has been scheduled in the Neurosurgery department;\n* Patient affiliated to a social security health insurance scheme;\n* Patient able to understand the objectives and risks of research and to give informed, dated and signed consent;\n* Patient having been informed of the results of the prior medical examination;\n* Women of childbearing age provided that a negative blood pregnancy test is recorded at the inclusion visit and effective contraception used throughout the study.\n\nExclusion criteria:\n\n* Patient with a history of lumbar spinal surgery (multiple herniated discs, herniated disc other than lumbar);\n* Patient with HIV, active cancer, HBV, HCV (verified by interview);\n* Patient on long-term systemic corticosteroid therapy;\n* Patient with an ASA score \\> 3 during the consultation with the anesthesiologist;\n* Inability to give the patient informed information (patient in an emergency or life-threatening situation, difficulties in understanding);\n* Patient in exclusion period (determined by a previous or ongoing study);\n* Subject under safeguard of justice;\n* Subject under curatorship;\n* Pregnancy;\n* Breastfeeding.","ALL","18 Years",{"count":75,"type":76},60,"ESTIMATED","INTERVENTIONAL",[79],"PHASE3","The prevalence of post-surgical lumbar neuropathic radiculopathy is approximately 30%. Poor response to the treatments recommended for neuropathic pain, namely antidepressants and\u002For gabapentinoids, requires the development of new techniques to prevent this chronic pain. Certain well-tolerated techniques, such as the administration of plasma enriched with platelets and fibrin (PRF), are increasingly used in regenerative medicine for their anti-inflammatory and analgesic properties. Thus, a periradicular intraoperative application of PRF may have an analgesic effect on the intensity of residual postsurgical neuropathic pain after disc herniation surgery.",[82,83],"Neuropathic Pain","Chronic Postsurgical Pain",[85,86,87,88],"Neuropathic pain","Chronic postsurgical pain prevention","Intraoperative platelet rich fibrin","Disc herniation surgery","2026-06-05",{"date":91,"type":92},"2026-06-08","ACTUAL",{"date":94,"type":92},"2022-02-23",{"date":96,"type":76},"2028-01",{"name":5,"class":6},1]